Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more
Market Cap & Net Worth: Pmv Pharmaceuticals Inc (PMVP)
Pmv Pharmaceuticals Inc (NASDAQ:PMVP) has a market capitalization of $83.01 Million ($83.01 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19594 globally and #7192 in its home market, demonstrating a -4.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pmv Pharmaceuticals Inc's stock price $1.56 by its total outstanding shares 53211507 (53.21 Million).
Pmv Pharmaceuticals Inc Market Cap History: 2020 to 2026
Pmv Pharmaceuticals Inc's market capitalization history from 2020 to 2026. Data shows change from $3.27 Billion to $83.01 Million (-44.05% CAGR).
Index Memberships
Pmv Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #538 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1792 of 3165 |
Weight: Pmv Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pmv Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pmv Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PMVP by Market Capitalization
Companies near Pmv Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Pmv Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pmv Pharmaceuticals Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Pmv Pharmaceuticals Inc's market cap moved from $3.27 Billion to $ 83.01 Million, with a yearly change of -44.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $83.01 Million | +24.80% |
| 2025 | $66.51 Million | -17.22% |
| 2024 | $80.35 Million | -51.29% |
| 2023 | $164.96 Million | -64.37% |
| 2022 | $462.94 Million | -62.34% |
| 2021 | $1.23 Billion | -62.45% |
| 2020 | $3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pmv Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.01 Million USD |
| MoneyControl | $83.01 Million USD |
| MarketWatch | $83.01 Million USD |
| marketcap.company | $83.01 Million USD |
| Reuters | $83.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.